Nutex Health (NUTX) Fundamental Analysis: Revenue, Earnings & Valuation

6.50 / 10

Outperform

Fundamentally, Nutex scores 6.5/10 and is rated Outperform. Key strengths are PB‑ROE and Cash‑MV, while Revenue‑MV and Cash‑UP are weaker. Factor analysis shows high‑group performance in earnings growth and cash flow, supporting a positive valuation.

Analysis Checks(8/10)

Revenue-MV

Value0.14

Score1/3

Weight6.65%

1M Return3.16%

Net cash flow from operating activities per share (YoY growth rate %)

Value733.46

Score3/3

Weight12.61%

1M Return5.35%

PB-ROE

Value-0.07

Score2/3

Weight1.72%

1M Return0.81%

Basic earnings per share (YoY growth rate %)

Value8.80

Score3/3

Weight10.56%

1M Return4.72%

Total profit (YoY growth rate %)

Value122.88

Score3/3

Weight11.38%

1M Return5.14%

Net cash flow from operating activities (YoY growth rate %)

Value971.68

Score3/3

Weight12.85%

1M Return5.57%

Cash-UP

Value-0.54

Score1/3

Weight1.32%

1M Return0.66%

Diluted earnings per share (YoY growth rate %)

Value8.15

Score3/3

Weight11.22%

1M Return5.00%

Asset-MV

Value-0.55

Score2/3

Weight15.22%

1M Return5.83%

Cash-MV

Value0.83

Score3/3

Weight16.47%

1M Return6.61%

Is NUTX fundamentally strong?

NUTX scores 6.50/10 on fundamentals and holds a Discounted valuation at present. Backed by its 23.13% ROE, 20.61% net margin, 9.36 P/E ratio, 1.56 P/B ratio, and 8.80% earnings growth, these metrics solidify its Outperform investment rating.